Agilon Health soars after surpassing Q1 expectations
Stock rose by more than 115% after multiple financial metrics improved
Rowan Dunne
Agilon Health Inc NYSEAGL shares soared on Thursday after the company released first quarter results exceeding expectations of analysts.
The stock more than doubled at one point during the session before settling with substantial gains, reflecting investor reaction to the improved earnings and updated guidance. It reached an intraday high of US$63.87.
For full-year 2026, Agilon is now projecting Adjusted EBITDA between US$10 million and US$40 million — a meaningful improvement from its previous range of negative US$15 million to positive US$15 million.
Agilon partners with primary care doctors who treat Medicare patients. It helps them move from being paid for each visit or test to a fixed monthly payment per patient. If the doctors keep patients healthier and reduce expensive hospital visits, both Agilon and the doctors keep more of that money as profit. If costs run too high, they lose money.
Agilon provides the software, data analytics and extra care support to make this work. The company itself earns revenue by receiving these fixed payments from Medicare Advantage insurance plans for each patient it manages.
Read more: Breath Diagnostics advances pre-op pneumonia screening with FDA breakthrough designation
Q1 highlights
The company reported first quarter revenue of US$1.42 billion, above analyst estimates of roughly US$1.38 billion. Adjusted EBITDA reached US$54 million compared with expectations near US$36 million.
GAAP earnings per share came in at US$1.80 against consensus around US$0.83 to US$0.93. Furthermore, medical margin increased to US$149 million from US$128 million a year earlier.
Membership stood at 536,000 at the end of the quarter, down from the prior year after the company exited certain markets and contracts to improve profitability. For these financial successes, management has pointed to certain Medicare programs where Agilon takes on full financial responsibility for patients’ total care costs and early wins from its technology and clinical programs.
Analysts have more bullish outlook
Deutsche Bank AG NYSEDB FRADBK upgraded the stock to Buy from Hold and lifted its price target to US$49. Additionally, Jefferies Financial Group Inc NYSEJEF raised its rating to Buy from Hold with a US$48 target, noting improved visibility into 2026 and 2027 rates.
The earnings release coincided with the start date of new CEO Tim O’Rourke. O’Rourke previously led Help at Home, a large provider of in-home care services for Medicare and Medicaid patients. He also spent 17 years at Humana Inc NYSEHUM FRAHUM in multiple roles.
While the quarter showed progress on margins and operational metrics, Agilon Health continues to face challenges. These include managing membership growth without sacrificing profitability and navigating annual Medicare rate negotiations.
Read more: Prestigious medtech intelligence firm recognizes Breath Diagnostics for innovation
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
